OCS

OculisD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

15%

Probability

Target price

$21.00

Analysis reference price unavailable

Analysis 2026-06-02 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$13.00

Analysis reference price unavailable

Analysis 2026-06-02 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$5.00

Analysis reference price unavailable

Analysis 2026-06-02 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-06-02

AI commentary

The reaction is negative: secondary coverage flagged a more than 20% drop after the DME miss, and the company source confirms the core issue was endpoint failure rather than a balance-sheet problem. Cash runway into 2H 2029 reduces near-term financing risk, but coverage is thin and analyst revision data are unavailable, so this stays a cautious monitoring setup rather than a high-conviction bullish re-entry.

RankAlpha Sentiment Codex - 2026-06-02

Open full AI memo

Evidence flagged

future-looking catalyst discovery is still SERP-only and has not been confirmed by a primary source

Impact

tentative

Confidence

AI events

2026-05-29eventDIAMOND Phase 3 missed the primary DME vision endpointHigh impact

Company-published DIAMOND-1 and DIAMOND-2 topline results showed OCS-01 did not meet the primary BCVA endpoint or the key at least 15-letter gain endpoint, and Oculis said it does not plan to pursue an FDA filing for DME [#PR-EARNINGS-2026-05-29].

2026-06-06catalystPost-readout selloff may keep sentiment volatileMedium impact

Secondary coverage flagged a more than 20% drop after the trial miss, so near-term trading could stay headline-driven while the market digests how much value now rests on the remaining pipeline [#SERP-1].

2026-12-31catalystPipeline refocus keeps Privosegtor and Licaminlimab fundedHigh impact

Management is reallocating resources to Privosegtor PIONEER in optic neuropathies and Licaminlimab PREDICT-1 in dry eye, with $278 million of cash and runway into 2H 2029 supporting the remaining late-stage portfolio [#PR-EARNINGS-2026-05-29].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-02 • Updated nightlySource: Internal modelMethodology